Posts tagged orthopedics
Ladenburg starts BioTime at buy

Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday.

“We view BioTime as roughly halfway through a restructuring designed to unlock shareholder value through separation of non-core assets and accelerated development of the company's cell therapy programs in ophthalmetry, aesthetics and orthopedics,” writes analyst Kevin DeGeeter.

Read More